Latest Period
Q1 2026
Security Snapshot
BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT) Institutional Ownership
CUSIP: 107924102
13F Institutional Holders and Ownership History from Q3 2025 to Q1 2026
Institutions Reporting
67
Shares (Excl. Options)
57,435,188
Price
$8.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- BBOT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 57,435,188
- Total 13F value
- $513,833,746
- Portfolio coverage rank
- 0%
- Share change
- -541,057
- Value change
- -$6,100,446
- Number of holders
- 67
- Shares outstanding
- 80,458,364
- SEC-reported price per share
- $8.72
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BBOT - BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 107924102.
- 67 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 52 to 67 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $724,704,890 to $513,833,746.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 67 institutions filings for Q1 2026.
Security key
107924102
Latest holder period
Q1 2026
13F holders
67
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
BBOT full holder history
BridgeBio Oncology Therapeutics, Inc. SEC filings
BridgeBio Oncology Therapeutics, Inc. company facts
BridgeBio Oncology Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 107924102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
BBOT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Helix Holdings II LLC | 23% | 17,878,594 | Bihua Chen | 11 Aug 2025 | ||||
| BridgeBio Pharma LLC | 18% | 13,878,554 | BridgeBio Pharma LLC | 11 Aug 2025 | ||||
| Flynn James E | 6.2% | 4,885,446 | Deerfield Management Company, L.P. | 11 Aug 2025 | ||||
| BC Global Opportunities IX LP | 5.5% | $42,740,663 | 4,365,747 | BC Global Opportunities IX LP | 04 Sep 2025 | |||
| CITADEL ADVISORS LLC | 3.2% | $29,391,684 | 2,538,142 | Kenneth Griffin | 30 Sep 2025 | |||
| Adage Capital Management, L.P. | 1.9% | $17,226,651 | 1,487,621 | Adage Capital Management, L.P. | 30 Sep 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.1% | $10,248,786 | 885,042 | T. Rowe Price Associates, Inc. | 30 Sep 2025 |
As of 31 Mar 2026, 67 institutional investors reported holding 57,435,188 shares of BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT). This represents 71% of the company’s total 80,458,364 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
67%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 22% | 17,878,594 | 0% | 8.1% | $160,013,416 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 6.1% | 4,885,446 | 0% | 0.52% | $43,724,742 |
| Omega Fund Management, LLC | 4.1% | 3,289,661 | 0% | 18% | $29,442,466 |
| EcoR1 Capital, LLC | 3.5% | 2,823,126 | 0% | 1.1% | $25,266,978 |
| Alphabet Inc. | 3.5% | 2,823,126 | 0% | 0.63% | $25,266,978 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.5% | 2,818,348 | -3% | 0% | $25,224,215 |
| ENAVATE SCIENCES GP, LLC | 3.3% | 2,626,946 | 0% | 6.7% | $23,511,167 |
| CITADEL ADVISORS LLC | 3.1% | 2,528,762 | -0.06% | 0.02% | $22,632,420 |
| NOVO HOLDINGS A/S | 2.7% | 2,185,923 | +11% | 1.6% | $19,564,011 |
| BlackRock, Inc. | 2.6% | 2,088,297 | +0.17% | 0% | $18,690,258 |
| Laurion Capital Management LP | 2.4% | 1,922,656 | +31% | 1.6% | $17,207,771 |
| ARMISTICE CAPITAL, LLC | 1.7% | 1,328,000 | +33% | 0.39% | $11,885,600 |
| Aisling Capital Management LP | 1.3% | 1,018,018 | +80% | 1.9% | $9,111,261 |
| Paradigm Biocapital Advisors LP | 1.1% | 868,213 | -62% | 0.16% | $7,770,506 |
| Octagon Capital Advisors LP | 0.89% | 719,000 | -31% | 0.71% | $6,435,050 |
| ROYCE & ASSOCIATES LP | 0.79% | 636,522 | 0.06% | $5,696,872 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.72% | 579,234 | +3.1% | 0% | $5,186,709 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.67% | 541,181 | -50% | 0.08% | $4,697,451 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.67% | 538,441 | 0% | 0% | $4,819,047 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.54% | 437,889 | -45% | 0% | $3,920,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.5% | 400,000 | -71% | 0.01% | $3,580,000 |
| Ensign Peak Advisors, Inc | 0.4% | 320,874 | 0.01% | $2,871,822 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.36% | 290,806 | +4.2% | 0% | $2,602,714 |
| Casdin Capital, LLC | 0.35% | 282,312 | 0% | 0.19% | $2,526,692 |
| Ikarian Capital, LLC | 0.34% | 270,231 | +23% | 0.35% | $2,418,568 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Latest
Q1 2026
Rows shown
1-3 of 3